Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Bos taurus | Dihydrofolate reductase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.1051 | 0.5167 | 1 |
Treponema pallidum | flavodoxin | 0.0402 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0402 | 0 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.1051 | 0.5167 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.1051 | 0.5167 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.1051 | 0.5167 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1051 | 0.5167 | 0.5167 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.1051 | 0.5167 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.1051 | 0.5167 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0402 | 0 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.1051 | 0.5167 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.1051 | 0.5167 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.0931 | 0.4216 | 0.8159 |
Leishmania major | p450 reductase, putative | 0.1051 | 0.5167 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.1051 | 0.5167 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0649 | 0.1966 | 0.3805 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.1051 | 0.5167 | 0.5167 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0649 | 0.1966 | 0.2407 |
Trichomonas vaginalis | sulfite reductase, putative | 0.1051 | 0.5167 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0931 | 0.4216 | 0.8159 |
Brugia malayi | FAD binding domain containing protein | 0.1051 | 0.5167 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0931 | 0.4216 | 0.8159 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1051 | 0.5167 | 1 |
Giardia lamblia | Hypothetical protein | 0.0931 | 0.4216 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.1051 | 0.5167 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.1051 | 0.5167 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0521 | 0.0951 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1051 | 0.5167 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0402 | 0 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.1051 | 0.5167 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0521 | 0.0951 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0931 | 0.4216 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0402 | 0 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.1051 | 0.5167 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1658 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0649 | 0.1966 | 0.1966 |
Chlamydia trachomatis | sulfite reductase | 0.0649 | 0.1966 | 0.5 |
Brugia malayi | flavodoxin family protein | 0.1051 | 0.5167 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0529 | 0.1015 | 0.0151 |
Trypanosoma cruzi | p450 reductase, putative | 0.1051 | 0.5167 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0402 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.1051 | 0.5167 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 13 % | Growth inhibition of human K562 cells at 10 uM after 48 hrs | ChEMBL. | 25139568 |
IC50 (binding) | = 7 uM | Inhibition of bovine liver DHFR | ChEMBL. | 25139568 |
IZ (functional) | = 8 mm | Antimicrobial activity against Escherichia coli assessed as inhibition zone at 200 ug/disk after 24 hrs by disc-diffusion method | ChEMBL. | 25139568 |
IZ (functional) | = 8 mm | Antimicrobial activity against Candida albicans assessed as inhibition zone at 200 ug/disk after 24 hrs by disc-diffusion method | ChEMBL. | 25139568 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.